# Ensysce Biosciences, Inc.: financial statements, quarterly

ENSC · Nasdaq · CIK 1716947 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ensc.md) · [Financials](/companies/ensc/financials.md) · [Filings](/companies/ensc/filings.md) · [Insiders](/companies/ensc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ensc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [435](/filings/0001493152-24-044768.md) | [515 d](/filings/0001493152-25-009703.md) | [306](/filings/0001641172-25-009955.md) | [182](/filings/0001641172-25-023512.md) | [3,419](/filings/0001493152-25-023498.md) | [1,304 d](/filings/0001493152-26-013633.md) | [1,320](/filings/0001493152-26-023811.md) | [1,371](/filings/0001493152-26-037817.md) | [493](/filings/0001493152-25-023498.md) | [1,882 d](/filings/0001493152-26-013633.md) | [961](/filings/0001493152-26-023811.md) | [1,164](/filings/0001493152-26-037817.md) |
| Research and development | $k | [1,915](/filings/0001493152-24-044768.md) | [2,233 d](/filings/0001493152-25-009703.md) | [779](/filings/0001641172-25-009955.md) | [947](/filings/0001641172-25-023512.md) | [1,691](/filings/0001493152-25-023498.md) | [3,803 d](/filings/0001493152-26-013633.md) | [1,886](/filings/0001493152-26-023811.md) | [1,923](/filings/0001493152-26-037817.md) | [2,955](/filings/0001493152-25-023498.md) | [3,613 d](/filings/0001493152-26-013633.md) | [3,347](/filings/0001493152-26-023811.md) | [2,472](/filings/0001493152-26-037817.md) |
| Selling, general and administrative | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $k | [(2,707)](/filings/0001493152-24-044768.md) | [(3,156) d](/filings/0001493152-25-009703.md) | [(1,843)](/filings/0001641172-25-009955.md) | [(1,955)](/filings/0001641172-25-023512.md) | [645](/filings/0001493152-25-023498.md) | [(3,576) d](/filings/0001493152-26-013633.md) | [(1,968)](/filings/0001493152-26-023811.md) | [(1,751)](/filings/0001493152-26-037817.md) | [(3,741)](/filings/0001493152-25-023498.md) | [(2,782) d](/filings/0001493152-26-013633.md) | [(3,562)](/filings/0001493152-26-023811.md) | [(2,576)](/filings/0001493152-26-037817.md) |
| Interest expense | $k | [7.6](/filings/0001493152-23-040091.md) | [345 d](/filings/0001493152-24-009993.md) | [1,248](/filings/0001493152-24-018718.md) | [27.6](/filings/0001641172-25-023512.md) | [4.1](/filings/0001493152-25-023498.md) | [10.8 d](/filings/0001493152-26-013633.md) | [3.9](/filings/0001493152-26-023811.md) | [3.2](/filings/0001493152-26-037817.md) | [6.4](/filings/0001493152-25-023498.md) | [5.4 d](/filings/0001493152-26-013633.md) | [3.9](/filings/0001493152-26-023811.md) | [0.3](/filings/0001493152-26-037817.md) |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(2,691)](/filings/0001493152-24-044768.md) | [(3,504) d](/filings/0001493152-25-009703.md) | [(3,117)](/filings/0001641172-25-009955.md) | [(1,968)](/filings/0001641172-25-023512.md) | [662](/filings/0001493152-25-023498.md) | [(3,564) d](/filings/0001493152-26-013633.md) | [(1,946)](/filings/0001493152-26-023811.md) | [(1,734)](/filings/0001493152-26-037817.md) | [(3,729)](/filings/0001493152-25-023498.md) | [(2,768) d](/filings/0001493152-26-013633.md) | [(3,556)](/filings/0001493152-26-023811.md) | [(2,571)](/filings/0001493152-26-037817.md) |
| Diluted EPS | $ per share | [(0.87)](/filings/0001493152-24-044768.md) | not reported | [(8.21)](/filings/0001641172-25-009955.md) | [(3.35)](/filings/0001641172-25-023512.md) | [1.00](/filings/0001493152-25-023498.md) | not reported | [(1.39)](/filings/0001493152-26-023811.md) | [(0.79)](/filings/0001493152-26-037817.md) | [(1.29)](/filings/0001493152-25-023498.md) | not reported | [(0.52)](/filings/0001493152-26-023811.md) | [(0.20)](/filings/0001493152-26-037817.md) |
| Basic EPS | $ per share | [(0.87)](/filings/0001493152-24-044768.md) | not reported | [(8.21)](/filings/0001641172-25-009955.md) | [(3.35)](/filings/0001641172-25-023512.md) | [1.00](/filings/0001493152-25-023498.md) | not reported | [(1.39)](/filings/0001493152-26-023811.md) | [(0.79)](/filings/0001493152-26-037817.md) | [(1.29)](/filings/0001493152-25-023498.md) | not reported | [(0.52)](/filings/0001493152-26-023811.md) | [(0.20)](/filings/0001493152-26-037817.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: not reported
- Net income: us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $k | [1,464](/filings/0001493152-23-040091.md) | [1,124](/filings/0001493152-25-009703.md) | [3,404](/filings/0001493152-24-018718.md) | [1,043](/filings/0001493152-24-032263.md) | [4,154](/filings/0001493152-24-044768.md) | [3,502](/filings/0001493152-26-013633.md) | [3,052](/filings/0001641172-25-009955.md) | [2,212](/filings/0001641172-25-023512.md) | [1,673](/filings/0001493152-25-023498.md) | [4,310](/filings/0001493152-26-037817.md) | [745](/filings/0001493152-26-023811.md) | [677](/filings/0001493152-26-037817.md) |
| Current assets | $k | [2,758](/filings/0001493152-23-040091.md) | [2,289](/filings/0001493152-25-009703.md) | [4,697](/filings/0001493152-24-018718.md) | [2,460](/filings/0001493152-24-032263.md) | [9,091](/filings/0001493152-24-044768.md) | [5,345](/filings/0001493152-26-013633.md) | [4,401](/filings/0001641172-25-009955.md) | [5,282](/filings/0001641172-25-023512.md) | [2,928](/filings/0001493152-25-023498.md) | [7,245](/filings/0001493152-26-037817.md) | [2,009](/filings/0001493152-26-023811.md) | [2,846](/filings/0001493152-26-037817.md) |
| Total assets | $k | [3,219](/filings/0001493152-23-040091.md) | [2,708](/filings/0001493152-25-009703.md) | [5,074](/filings/0001493152-24-018718.md) | [2,796](/filings/0001493152-24-032263.md) | [9,385](/filings/0001493152-24-044768.md) | [5,597](/filings/0001493152-26-013633.md) | [4,612](/filings/0001641172-25-009955.md) | [5,574](/filings/0001641172-25-023512.md) | [3,179](/filings/0001493152-25-023498.md) | [7,452](/filings/0001493152-26-037817.md) | [2,168](/filings/0001493152-26-023811.md) | [2,957](/filings/0001493152-26-037817.md) |
| Current liabilities | $k | [2,031](/filings/0001493152-23-040091.md) | [3,333](/filings/0001493152-25-009703.md) | [1,636](/filings/0001493152-24-018718.md) | [1,307](/filings/0001493152-24-032263.md) | [2,802](/filings/0001493152-24-044768.md) | [2,207](/filings/0001493152-26-013633.md) | [1,761](/filings/0001641172-25-009955.md) | [2,513](/filings/0001641172-25-023512.md) | [2,305](/filings/0001493152-25-023498.md) | [4,568](/filings/0001493152-26-037817.md) | [2,837](/filings/0001493152-26-023811.md) | [4,068](/filings/0001493152-26-037817.md) |
| Total liabilities | $k | [2,061](/filings/0001493152-23-040091.md) | [3,359](/filings/0001493152-25-009703.md) | [1,654](/filings/0001493152-24-018718.md) | [1,316](/filings/0001493152-24-032263.md) | [2,805](/filings/0001493152-24-044768.md) | [2,217](/filings/0001493152-26-013633.md) | [1,891](/filings/0001641172-25-009955.md) | [2,514](/filings/0001641172-25-023512.md) | [2,305](/filings/0001493152-25-023498.md) | [4,568](/filings/0001493152-26-037817.md) | [2,837](/filings/0001493152-26-023811.md) | [4,068](/filings/0001493152-26-037817.md) |
| Shareholders' equity | $k | [1,485](/filings/0001493152-23-040091.md) | [(323)](/filings/0001493152-25-009703.md) | [3,749](/filings/0001493152-24-018718.md) | [1,808](/filings/0001493152-24-032263.md) | [6,908](/filings/0001493152-24-044768.md) | [3,708](/filings/0001493152-26-013633.md) | [3,049](/filings/0001641172-25-009955.md) | [3,389](/filings/0001641172-25-023512.md) | [1,203](/filings/0001493152-25-023498.md) | [3,214](/filings/0001493152-26-037817.md) | [(340)](/filings/0001493152-26-023811.md) | [(782)](/filings/0001493152-26-037817.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,263) d](/filings/0001493152-24-044768.md) | [(1,802) d](/filings/0001493152-25-009703.md) | [(3,408)](/filings/0001641172-25-009955.md) | [(2,310) d](/filings/0001641172-25-023512.md) | [(1,020) d](/filings/0001493152-25-023498.md) | [(764) d](/filings/0001493152-26-013633.md) | [(1,707)](/filings/0001493152-26-023811.md) | [(2,707) d](/filings/0001493152-26-037817.md) | [(1,866) d](/filings/0001493152-25-023498.md) | [(1,526) d](/filings/0001493152-26-013633.md) | [(3,501)](/filings/0001493152-26-023811.md) | [(1,962) d](/filings/0001493152-26-037817.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001493152-26-013633.md) | not reported | not reported |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.2](/filings/0001493152-23-040091.md) | [1.1](/filings/0001493152-24-018718.md) | [2.3](/filings/0001493152-24-032263.md) | [3.1](/filings/0001493152-24-044768.md) | [0.4](/filings/0001641172-25-009955.md) | [0.6](/filings/0001641172-25-023512.md) | [0.7](/filings/0001493152-25-023498.md) | [1.4](/filings/0001493152-26-023811.md) | [2.2](/filings/0001493152-26-037817.md) | [2.9](/filings/0001493152-25-023498.md) | [6.8](/filings/0001493152-26-023811.md) | [13.0](/filings/0001493152-26-037817.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 19,456,794 at 2026-08-12, from the cover of the [10-Q filed 2026-08-13](/filings/0001493152-26-037817.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.